
Arcellx (ACLX) Stock Forecast & Price Target
Arcellx (ACLX) Analyst Ratings
Bulls say
Arcellx Inc. demonstrates a robust growth trajectory, with Carvykti sales averaging a 32% quarter-over-quarter increase over the past three years, indicating strong market demand. The expanding access to community physicians capable of administering CAR T therapies has risen significantly from 29% to 47% within the same timeframe, underscoring the increasing acceptance and implementation of innovative treatments. Furthermore, strong clinical data from Phase 1 and Phase 2 trials for anito-cel, combined with potential market dominance projected to achieve $4.7 billion in sales by 2035, enhances the company's growth prospects in a rapidly expanding CAR T market.
Bears say
Arcellx Inc. faces a negative outlook primarily due to its sales estimates for anti-cel, which fall short of consensus projections for the overall CAR T market in multiple myeloma, with 2035 sales estimated at $11.5 billion compared to $16.5 billion. The company also grapples with significant risks, including the potential for unsuccessful drug pipeline execution, ongoing drug pricing control discussions in Washington, D.C., and adverse conditions in biotechnology capital markets. Additionally, despite promising clinical data, barriers to community adoption of CAR T therapies suggest a challenging path forward, further complicating the company’s revenue prospects.
This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.
Arcellx (ACLX) Analyst Forecast & Price Prediction
Start investing in Arcellx (ACLX)
Order type
Buy in
Order amount
Est. shares
0 shares